Meyka Pro banner
AtriCure, Inc.

AtriCure, Inc. Fundamental Analysis (NASDAQ: ATRC)

ATRCNASDAQ
HealthcareMedical - Instruments & Supplies
$35.04
$2.04(6.18%)
U.S. Market opens in 14h 24m

AtriCure, Inc. Fundamental Analysis (NASDAQ: ATRC)

AtriCure, Inc. (NASDAQ: ATRC) shows weak financial fundamentals with a PE ratio of 153.69, profit margin of 1.85%, and ROE of 2.14%. The company generates $0.6B in annual revenue with strong year-over-year growth of 14.88%.

Key Strengths

PEG Ratio0.13
Current Ratio4.22

Areas of Concern

ROE2.14%
Operating Margin2.44%
We analyze ATRC's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 48.7/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

D
48.7/100

We analyze ATRC's fundamental strength across five key dimensions:

Efficiency Score

Weak

ATRC struggles to generate sufficient returns from assets.

ROA > 10%
1.56%

Valuation Score

Moderate

ATRC shows balanced valuation metrics.

PE < 25
153.69
PEG Ratio < 2
0.13

Growth Score

Excellent

ATRC delivers strong and consistent growth momentum.

Revenue Growth > 5%
14.88%
EPS Growth > 10%
74.74%

Financial Health Score

Excellent

ATRC maintains a strong and stable balance sheet.

Debt/Equity < 1
0.14
Current Ratio > 1
4.22

Profitability Score

Moderate

ATRC maintains healthy but balanced margins.

ROE > 15%
213.54%
Net Margin ≥ 15%
1.85%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is ATRC Expensive or Cheap?

P/E Ratio

ATRC trades at 153.69 times earnings. This suggests a premium valuation.

153.69

PEG Ratio

When adjusting for growth, ATRC's PEG of 0.13 indicates potential undervaluation.

0.13

Price to Book

The market values AtriCure, Inc. at 3.21 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

3.21

EV/EBITDA

Enterprise value stands at 67.26 times EBITDA. This signals the market has high growth expectations.

67.26

How Well Does ATRC Make Money?

Net Profit Margin

For every $100 in sales, AtriCure, Inc. keeps $1.85 as profit after all expenses.

1.85%

Operating Margin

Core operations generate 2.44 in profit for every $100 in revenue, before interest and taxes.

2.44%

ROE

Management delivers $2.14 in profit for every $100 of shareholder equity.

2.14%

ROA

AtriCure, Inc. generates $1.56 in profit for every $100 in assets, demonstrating efficient asset deployment.

1.56%

Following the Money - Real Cash Generation

Operating Cash Flow

AtriCure, Inc. produces operating cash flow of $67.20M, showing steady but balanced cash generation.

$67.20M

Free Cash Flow

AtriCure, Inc. produces free cash flow of $56.01M, offering steady but limited capital for shareholder returns and expansion.

$56.01M

FCF Per Share

Each share generates $1.11 in free cash annually.

$1.11

FCF Yield

ATRC converts 3.04% of its market value into free cash.

3.04%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

153.69

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.13

vs 25 benchmark

P/B Ratio

Price to book value ratio

3.21

vs 25 benchmark

P/S Ratio

Price to sales ratio

3.04

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.14

vs 25 benchmark

Current Ratio

Current assets to current liabilities

4.22

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.02

vs 25 benchmark

ROA

Return on assets percentage

0.02

vs 25 benchmark

ROCE

Return on capital employed

0.02

vs 25 benchmark

How ATRC Stacks Against Its Sector Peers

MetricATRC ValueSector AveragePerformance
P/E Ratio153.6929.34 Worse (Expensive)
ROE2.14%470.00% Weak
Net Margin1.85%-71064.00% (disorted) Weak
Debt/Equity0.140.84 Strong (Low Leverage)
Current Ratio4.225.17 Strong Liquidity
ROA1.56%-26.00% (disorted) Weak

ATRC outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews AtriCure, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

128.32%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

79.03%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

354.57%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ